188 related articles for article (PubMed ID: 35401563)
1. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.
Zhou H; Xie X; Zhang T; Yang M; Zhou D; Yang T
Front Immunol; 2022; 13():850540. PubMed ID: 35401563
[TBL] [Abstract][Full Text] [Related]
2. Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?
Li TR; Zhang YD; Wang Q; Shao XQ; Li ZM; Lv RJ
BMC Neurosci; 2020 Mar; 21(1):13. PubMed ID: 32228575
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
Lin J; Xue M; Gao M; Yu P; Han S
Dermatol Ther (Heidelb); 2020 Aug; 10(4):863-867. PubMed ID: 32445174
[TBL] [Abstract][Full Text] [Related]
4. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.
Zhang L; Hao B; Geng Z; Geng Q
Front Immunol; 2021; 12():730666. PubMed ID: 35095833
[TBL] [Abstract][Full Text] [Related]
5. [Pediatric autoimmune encephalitis associated with anti-glutamic acid decarboxylase 65 antibody: two cases report and literature review].
Ren CH; Ren HT; Ren XT; Zhang WH; Li JW; Dai LF; Chen CH; Guan HZ; Fang F
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):47-52. PubMed ID: 33397004
[No Abstract] [Full Text] [Related]
6. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
7. Case report: Successful treatment of an anti-D2R and DPPX antibody-associated autoimmune encephalitis patient with high-dose methylprednisolone and intravenous immunoglobulin.
Lin Z; Zhou F; Ni L; Dong S; Fu G; Zhao J
Front Immunol; 2024; 15():1338714. PubMed ID: 38469308
[TBL] [Abstract][Full Text] [Related]
8. Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report.
Lin J; Zhu M; Mao X; Jin Z; Zhou M; Hong D
BMC Neurol; 2022 Jul; 22(1):242. PubMed ID: 35778696
[TBL] [Abstract][Full Text] [Related]
9. Cerebellar ataxia as a presenting symptom in a patient with anti-NMDA receptor encephalitis.
Poorthuis MHF; van Rooij JLM; Koch AH; Verdonkschot AEM; Leembruggen MM; Titulaer MJ
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e579. PubMed ID: 31355315
[No Abstract] [Full Text] [Related]
10. Toripalimab for the treatment of melanoma.
Tang B; Chi Z; Guo J
Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
12. Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor.
Saikawa H; Nagashima H; Maeda T; Maemondo M
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31892620
[TBL] [Abstract][Full Text] [Related]
13. [Cerebellar Ataxia and Autoantibodies].
Nanri K; Yoshikura N; Kimura A; Nakayama S; Otomo T; Shimohata T; Terashi H; Sato T; Yamada J
Brain Nerve; 2018 Apr; 70(4):371-382. PubMed ID: 29632285
[TBL] [Abstract][Full Text] [Related]
14. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies.
Muñiz-Castrillo S; Vogrig A; Joubert B; Pinto AL; Gonçalves D; Chaumont H; Rogemond V; Picard G; Fabien N; Honnorat J
Cerebellum; 2020 Oct; 19(5):715-721. PubMed ID: 32592031
[TBL] [Abstract][Full Text] [Related]
15. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report.
He J; Chen X; Cheng K; Lv W; Cao D; Li Z
BMC Neurol; 2023 Mar; 23(1):96. PubMed ID: 36870985
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis.
Luo C; Chen H; Wu H; Liu Y; Li G; Lun W
Front Immunol; 2023; 14():1298902. PubMed ID: 38077371
[TBL] [Abstract][Full Text] [Related]
18. Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia.
Mirabelli-Badenier M; Morana G; Pinto F; Uccelli A; Veneselli E; Battaglia FM; Biancheri R; Baglietto MG; Vincent A; Mancardi MM
Arch Neurol; 2012 Aug; 69(8):1064-6. PubMed ID: 22507885
[TBL] [Abstract][Full Text] [Related]
19. Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report.
Qu Y; Wang Z; Feng J; Wang L; Liu H; Liu D; Zhao Y; Yu R; Li W; Sun D; Yu H
Ann Palliat Med; 2021 Aug; 10(8):9267-9275. PubMed ID: 34488412
[TBL] [Abstract][Full Text] [Related]
20. "Hot Cross Bun" Sign in a Patient with Glutamic Acid Decarboxylase 65-KDa Isoform Associated Cerebellar Ataxia: Case Report and Review of the Literature.
Duan RN; He JZ; Cao LL
Cerebellum; 2024 Jun; 23(3):1204-1210. PubMed ID: 37948023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
